tirzepatide phase 3 The SURMOUNT-MAINTAIN 3b trial is testing if adults with obesity can maintain weight loss by continuing or reducing (vs placebo) after achieving results on the highest dose. #Tirzepatide https://t.co/FHyoDXDEYv SURMOUNT-3 study design This is

Long enough for most structural changes to return to baseline but short enough to maintain protocol feasibility

Semaglutide induces weight loss by mimicking the effects of the natural GLP-1 hormone

Users receive weekly check-ins and medication titration guidance coordinated with their provider

If you started in February, this takes you into April

Whilst gastrointestinal side effects such as nausea, vomiting, and abdominal discomfort are common with Rybelsus, there is no established direct link between this medication and stomach ulcers

Pharmacotherapies for post-bariatric weight regain: real-world comparative outcomes